182 results on '"Shepherd, F.A."'
Search Results
2. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
3. MA16.11 Consolidation EGFR-Tyrosine Kinase Inhibitor (TKI)vs. Durvalumab vs. Observation in Unresectable EGFR-Mutant Stage III NSCLC
4. A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer
5. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
6. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer
7. OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results
8. 296P Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
9. EP.12A.46 Age, Health Utility Scores (HUS), and Survival Outcomes in EGFR-Mutated Lung Cancer Patients Receiving 1L TKI Treatment.
10. P1.03F.03 Utility of Patient-Derived Xenograft and Xenograft-Derived Organoid Models with EGFR Mutation to Study EGFR-TKI Resistance.
11. EP08.02-082 Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
12. MA14.08 Longitudinal Symptoms and Health Utility Scores (HUS) in Patients Receiving PD-1 Inhibitors for Metastatic NSCLC
13. 1144P Clinical outcomes of NSCLC patients (pts) who had brain-only metastasis at time of stage IV diagnosis, by presence versus absence of EGFR/ALK mutations
14. EP02.04-009 Real World Survival Outcome Analysis of Adjuvant Therapies in Non-EGFR, Non-ALK Early Stage Resected NSCLC
15. EP04.01-001 Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience
16. 1191TiP Nivolumab-ipilimumab with cfDNA-guided treatment intensification as a chemotherapy-sparing strategy in metastatic non-small cell lung cancer (ATLAS)
17. 1058P Non-smokers with squamous lung cancers have a high incidence of HHV infections, DDR gene alterations and good prognosis
18. 1202TiP Evolution of the tumor immune microenvironment in hepatocellular carcinoma (HCC) and non-squamous non-small cell lung cancer (NSCLC) with liver metastases treated with atezolizumab and bevacizumab (INTEGRATE)
19. EP08.01-067 Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC
20. LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
21. EP.13D.12 International Consortium Real-World Outcomes in Extensive Disease Small Cell Lung Cancer Compared to IMPOWER133 And CASPIAN
22. EP.12A.09 Oligoprogression and Osimertinib Continuation Post-progression in Patients with EGFR-Mutations
23. 2P Single-cell profiling and integrative TCR analysis reveals tumor-mutation associated phenotypes and immune repertoire in lung adenocarcinoma
24. 1304P Investigator-initiated study of crizotinib in patients with MET activated advanced stage non-small cell lung cancer: A Canadian experience
25. 1287P Predictive value of weight and BSA in assessing toxicity during ALK-TKIs in non-small cell lung cancer
26. MA17.03 30 Years of International Real World Outcomes in Patients with Limited Disease Small Cell Lung Cancer
27. 181P Poor response to PD-1 inhibitors in metastatic non-small cell lung cancer (mNSCLC) patients with liver metastases may be mediated by myeloid populations
28. OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer
29. FP12.07 Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients
30. FP16.03 Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial
31. P45.05 Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival
32. OA08.04 Validation of Scalable, Automated Data Extraction in an Advanced Lung Cancer Patient Population
33. P59.17 EGFR Mutation Status, Liver Metastasis, and Overall Survival in Advanced Lung Adenocarcinoma Patients
34. P45.09 Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada
35. FP12.01 PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC
36. P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?
37. FP01.03 Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC
38. P45.07 Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC
39. MA08.02 Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort
40. 531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial
41. 1165P Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial
42. 1356P Cumulative incidence and baseline imaging patterns of brain metastases in advanced EGFR and ALK positive non-small cell lung cancer (NSCLC)
43. 1809P Evaluation of KRAS mutation subtype on survival in patients with metastatic non-small cell lung cancer receiving immunotherapy
44. 1298P PD-1 inhibitors combined with chemotherapy may preferentially improve survival in metastatic NSCLC with myeloid-mediated primary resistance to immunotherapy
45. 1243P Cumulative incidence and metastatic patterns of relapsed vs de novo stage IV non-small cell lung cancer (NSCLC) characterized by histology and EGFR status
46. 1350P Characteristics, treatment patterns and outcome of non-small cell lung cancer (NSCLC) patients presenting with brain-only metastatic disease
47. 2201P Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies
48. 2192P Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
49. LBA68 FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
50. 1353P Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.